Alzheimer’s Association Statement on European Medicines Agency Negative Opinion on Leqembi for the Treatment of Alzheimer’s Disease

CHICAGO, July 26, 2024 /PRNewswire/ — The Alzheimer’s Association is disappointed by today’s decision by the European Medicines Agency (EMA) to recommend against allowing Leqembi® to be marketed across the European Union. “The EMA has denied people living with Alzheimer’s and their…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.